The solution eases the problem of analyte/metal surface interactions when analyzing organic acids, organophosphates, oligonucleotides, phosphopeptides, acidic glycans, and phospholipids by reverse-phase and hydrophilic interaction chromatography.
The Waters Acquity Premier Solution from Waters Corporation is a liquid chromatograph featuring Waters’ MaxPeak High Performance Surface technology, which works to improve analytical data quality and eliminate the need for passivation.
Used in combination with Acquity Premier Columns, the solution is formulated to ease the problem of analyte/metal surface interactions when analyzing organic acids, organophosphates, oligonucleotides, phosphopeptides, acidic glycans, and phospholipids by reversed phase and hydrophilic interaction chromatography. Additionally, the solution:
“The Acquity Premier Solution represents our biggest innovation in separation science since UPLC,” said Ian King, senior vice-president, Global Products, Waters Corporation, in a Feb. 10, 2021 press release. “Chromatography has an immeasurable impact on the development of novel therapeutics and treatments for innumerable diseases. The result of decades of separations science know-how along with the combined efforts of our materials scientists, chemists, and engineers, Acquity Premier addresses a long-standing problem that has held back scientific progress long enough. We firmly believe it will redefine the value that separations science brings to scientific achievement.”
Source: Waters Corporation
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.